Auflistung Nach Schlagwort "phase 2 clinical trial (topic)"
Anzeige der Dokumente 1-14 von 14
-
Anti-cd20 agents for multiple sclerosis: Spotlight on ocrelizumab and ofatumumab
(2020)Until recently, in the pathogenesis of Multiple Sclerosis (MS), the contribution of B cells has been largely underestimated, and the disease was considered a T-cell-mediated disorder. However, newer evidence shows that B ... -
Functional characterization and anti-cancer action of the clinical phase II cardiac Na+/K+ ATPase inhibitor istaroxime: In vitro and in vivo properties and cross talk with the membrane androgen receptor
(2016)Sodium potassium pump (Na+/K+ ATPase) is a validated pharmacological target for the treatment of various cardiac conditions. Recent published data with Na+/K+ ATPase inhibitors suggest a potent anti-cancer action of these ... -
Immunotherapy of systemic sclerosis
(2018)Systemic sclerosis (SSc) is a chronic systemic disease characterized by microvasculopathy, immune activation, and extensive collagen deposition. Microvasculopathy and immune activation occur very early in the disease ... -
Myeloid-derived suppressor cells: Major figures that shape the immunosuppressive and angiogenic network in cancer
(2019)Myeloid-derived suppressor cells (MDSCs) constitute a vast population of immature myeloid cells implicated in various conditions. Most notably, their role in cancer is of great complexity. They exert immunosuppressive ... -
New therapeutic strategies for the treatment of male lower urinary tract symptoms
(2016)Male lower urinary tract symptoms (LUTS) are prevalent in the general population, especially in those of advanced age, and are characterized by notable diversity in etiology and presentation, and have been proven to cause ... -
Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications
(2016)Purpose: We aimed to provide a meta-analysis of the factors affecting vitreomacular traction (VMT) resolution after ocriplasmin use. A comprehensive systematic review of the complications after ocriplasmin use for VMT and ... -
P38 MAPK signaling in pemphigus: Implications for skin autoimmunity
(2013)p38 mitogen activated protein kinase (p38 MAPK) signaling plays a major role in the modulation of immune-mediated inflammatory responses and therefore has been linked with several autoimmune diseases. The extent of the ... -
-
Platelets in Systemic Sclerosis: the Missing Link Connecting Vasculopathy, Autoimmunity, and Fibrosis?
(2019)Purpose of Review: Platelets are no longer recognized solely as cell fragments regulating hemostasis. They have pleiotropic functions and they are linked directly or indirectly with the three cornerstones of systemic ... -
Safety and tolerability of β 3-adrenoceptor agonists in the treatment of overactive bladder syndrome - Insight from transcriptosome and experimental studies
(2016)Introduction: We have reviewed the safety and tolerability of β3-adrenoceptor agonists, specifically mirabegron and solabegron, a newly emerging drug class for the treatment of the overactive bladder syndrome. We discuss ... -
Targeting neuroendocrine prostate cancer: Molecular and clinical perspectives
(2015)Neuroendocrine prostate carcinoma, either co-present with the local adenocarcinoma disease or as a result of transdifferentiation later in time, was described as one major process of emerging resistance to androgen deprivation ... -
Transcranial magnetic stimulation (TMS) and repetitive TMS in multiple sclerosis
(2021)Multiple sclerosis (MS) is the most well-known autoimmune disorder of the central nervous system, and constitutes a major cause of disability, especially in young individuals. A wide array of pharmacological treatments is ... -
Treatment of posterior circulation symptomatic disease: A reappraisal may be needed
(2017)[No abstract available] -
Upadacitinib tartrate in rheumatoid arthritis
(2020)does not achieve low disease activity or remission despite the use of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and/or biological DMARDs (bDMARDs). The Janus kinase (JAK) inhibitors are the ...